 UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021. 